Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion from CellCept (MMF) to Myfortic (enteric-coated mycophenolic acid) in stable liver or kidney transplant patients with gastrointestinal adverse events
2004-001361-18Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate sodium in Kidney allograft status (RTx) and decompensated cirrhosis, sponsored by Novartis. Primary endpoints: Change in upper gastrointestinal symptom severity and Change in lower gastrointestinal symptom severity. Started Aug 2005; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
Kidney allograft status (RTx)decompensated cirrhosis
Beyond the preview
Go deeper on 2004-001361-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001361-18.